SANN Santhera Pharmaceuticals

Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day

Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day

Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the treatment of Duchenne Muscular Dystropy (DMD). The Company will also outline plans for further market expansion and provide an update on its strategic direction beyond DMD. The Company continues to evaluate opportunities to expand its rare disease portfolio as part of its strategy to establish itself as a leading specialty pharmaceutical company.

The CMD will feature presentations from Santhera’s leadership team, including Dario Eklund, CEO; Dr Shabir Hasham, Chief Medical Officer; and Catherine Isted, Chief Financial Officer. Additionally, Prof. Luca Bello MD, PhD, Associate professor of neurology, and neuromuscular clinician at the ​University of Padova, will provide insights into the significant unmet medical need and current treatment landscape for patients with DMD.

Dario Eklund, CEO of Santhera said: "The last 12 months have been a pivotal period for both the Company and DMD patients, as we began the global commercial roll-out of AGAMREE. Today, we are pleased to share an update on our strong progress with this breakthrough treatment and outline near and medium-term strategic goals for the Company. As we continue to execute our plans, our focus remains on improving patients’ quality of life whilst delivering value for our shareholders."

Event details:

Santhera’s Capital Market Day will be held today for institutional investors, analysts and business journalists from 2:00 p.m. CET to 6:00 p.m. at the Park Hyatt Hotel in Zurich and online. A Webcast link and replay will be available for this group on request – please send an email to .

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in China by the National Medical Products Administration (NMPA) and Hong Kong by the Department of Health (DoH). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix Therapeutics. For further information, please visit .

AGAMREE® is a trademark of Santhera Pharmaceuticals.

For further information please contact:

or

Catherine Isted, Chief Financial Officer

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

Attachment



EN
24/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Santhera Pharmaceuticals

 PRESS RELEASE

Santhera schlägt Dr. Melanie Rolli als neues Mitglied des Verwaltungsr...

Santhera schlägt Dr. Melanie Rolli als neues Mitglied des Verwaltungsrats vor «Ad hoc-Mitteilung gemäss Art. 53 KR»  Pratteln, Schweiz, 27. März 2025 - Santhera Pharmaceuticals (SIX: SANN) schlägt der kommenden Generalversammlung vom 20. Mai 2025 die Wahl von Dr. Melanie Rolli als unabhängiges Verwaltungsratsmitglied vor. Das bisherige Verwaltungsratsmitglied Dr. Otto Schwarz stellt sich nicht zur Wiederwahl. Thomas Meier, Präsident des Verwaltungsrats von Santhera, sagte: "Wir freuen uns sehr, dass Frau Dr. Rolli der Nominierung in den Verwaltungsrat zugestimmt hat. Wir sind überzeugt, d...

 PRESS RELEASE

Santhera proposes Dr. Melanie Rolli as new member of Board of Director...

Santhera proposes Dr. Melanie Rolli as new member of Board of Directors Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 27, 2025 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Melanie Rolli as an Independent Director at the upcoming Annual General Meeting to be held on May 20, 2025. Current Board member Dr. Otto Schwarz will not stand for re-election. Thomas Meier, Chairman of the Board of Directors of Santhera, said: "We are delighted Dr. Rolli has agreed to be nominated to join the Board; where we believe she would bring extensive strategic and oper...

 PRESS RELEASE

Santhera to share latest on commercial rollout of AGAMREE® and future ...

Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the treatment of Duchenne Muscular Dystropy (DMD). The Company will also outline plans for further market expansion and provide an update on its strategic direction beyond DMD. The Company continues to evaluate opportunities to expand its rare disease...

 PRESS RELEASE

Santhera informiert am Capital Markets Day über den aktuellen Stand de...

Santhera informiert am Capital Markets Day über den aktuellen Stand der kommerziellen Einführung von AGAMREE® und zukünftige strategische Prioritäten Pratteln, Schweiz, 24. März 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Unternehmen an seinem heutigen Capital Markets Day (CMD) in Zürich über die kommerziellen Fortschritte bei der weltweiten Markteinführung von AGAMREE® zur Behandlung von Duchenne-Muskeldystrophie (DMD) sprechen wird. Darüber hinaus wird das Unternehmen seine Pläne für die weitere Marktexpansion erläutern und über seine strategische Ausrichtung über D...

 PRESS RELEASE

Handelsupdate für das Gesamtjahr

Handelsupdate für das Gesamtjahr Ad hoc Ankündigung gemäß Art. 53 LR Pratteln, Schweiz, 4. März 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt heute ein Handelsupdate für das Geschäftsjahr 2024 und einen Ausblick für 2025 und darüber hinaus. Dario Eklund, CEO von Santhera, sagte: “Das Jahr 2024 war ein transformatives Jahr für Santhera, da wir unsere finanzielle Position gestärkt und die kommerzielle Einführung von AGAMREE® (Vamorolon) zur Behandlung der Duchenne-Muskeldystrophie (DMD) in wichtigen europäischen Märkten vorangetrieben haben. Wir bleiben entschlossen, unsere Strategie umz...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch